相关实验视频
Updated: May 13, 2025

Three-Dimensional 3D Tumor Spheroid Invasion Assay
Published on: May 1, 2015
ADORA2B促进了头部和部状细胞癌的增殖和迁移,并与免疫透有关
Pian Li1, Ke-Ling Pang2, Shuang-Jing Chen3
1Department of Oncology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
氨酸A2B受体 (ADORA2B) 驱动头癌的进展,并创造了一个免疫抑制瘤微环境. 向ADORA2B有可能改善HNSC患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 氨酸A2B受体 (ADORA2B) 在各种癌症中起作用,但其在头角状细胞癌 (HNSC) 中的功能尚不清楚.
- 这项研究调查了ADORA2B在HNSC中的表达,预后价值和治疗潜力.
研究的目的:
- 阐明ADORA2B在HNSC中的表达特征和预后意义.
- 探索ADORA2B在瘤微环境中的免疫调节作用.
- 评估针对HNSC中的ADORA2B的治疗潜力.
主要方法:
- 对ADORA2B表达和临床相关性TCGA和GEO数据集的生物信息学分析.
- 通过WGCNA和功能丰富分析,确定与ADORA2B相关的途径.
- 为了验证ADORA2B的致癌作用,进行了体外实验 (siRNA淘汰,CCK-8,殖民地形成,伤口愈合分析).
主要成果:
- 在HNSC中,ADORA2B过度表达,与晚期和低生存率 (OS,PFS) 相相关.
- 高ADORA2B表达与免疫抑制性瘤微环境和免疫检查点阻塞 (ICB) 疗法的有效性降低有关.
- 在ADORA2B中,ADORA2B抑制了HNSC细胞的增殖,迁移和殖民地形成.
结论:
- 在HNSC中,ADORA2B作为瘤驱动剂,促进瘤生长和免疫逃避.
- ADORA2B是一种潜在的诊断和预后生物标志物,向它可能会改善治疗结果.
- 向ADORA2B可以克服HNSC的治疗耐药性.
更多相关视频
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
11:28Isolation and Characterization of a Head and Neck Squamous Cell Carcinoma Subpopulation Having Stem Cell Characteristics
Published on: May 11, 2016
相关概念视频
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Tumor Immunotherapy
Abnormal Proliferation
The Tumor Microenvironment
Cancer Cell Migration through Invadopodia
Immunoglobulin-like Cell Adhesion Molecules
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...